{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"5.6","value":"4.2"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"7.2","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"description":"To demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST), version 1.1 in patients with advanced GIST following 2 or 3 regimens of prior treatment with a tyrosine kinase inhibitor (TKI), including imatinib, compared to patients treated with regorafenib. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.","dispersionType":"95% Confidence Interval","groups":[{"description":"300 mg PO QD avapritinib: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.","id":"OG000","title":"Avapritinib"},{"description":"160 mg PO QD regorafenib: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).","id":"OG001","title":"Regorafinib"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat Population that included all patients randomized to study.","reportingStatus":"POSTED","timeFrame":"24 Months","title":"Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1","type":"PRIMARY","unitOfMeasure":"months"}